[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] PHIPPS A I, LIMBURG P J, BARON J A, et al.Association between molecular subtypes of colorectal cancer and patient survival[J]. Gastroenterology, 2015, 148(1): 77-87.
[3] 孙屏, 郭兴美, 吕慧, 等. 微卫星不稳定和RAS基因突变与Ⅲ~Ⅳ期大肠癌预后的相关性[J]. 临床与病理杂志, 2020, 40(10): 2569-2580.
[4] 方琳, 刘超, 张纯慧, 等. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[5] LUO H Y, LI Y H, WANG W, et al.Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety[J]. Ann Oncol, 2016, 27(6): 1074-1081.
[6] DÍAZ RUBIO E, GÓMEZ ESPAÑA A, MASSUTÍ B, et al. First‐line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single‐agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase Ⅲ MACRO TTD study[J]. Oncologist, 2012, 17(1): 15-25.
[7] GROTHEY A M, CUTSEM E V P, SOBRERO A M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863): 303-312.
[8] LI J, QIN S, XU R, et al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16(6): 619-629.
[9] BEKAII-SAAB T S, OU F S, AHN D H, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2019, 20(8): 1070-1082.
[10] LE D T, URAM J N, WANG H, et al.PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
[11] FUKUOKA S, HARA H, TAKAHASHI N, et al.Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ⅰb Trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18): 2053-2061.
[12] GOU M, YAN H, TIE L E, et al. Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China[J]. J Clin Oncol, 2020, 38(Suppl 15): abstr 4028.
[13] WANG F, HE M M, YAO Y C, et al.A phase Ⅰb/Ⅱ clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer[J]. Ann Oncol, 2020, 31: S425. |
